Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms

With Bristol Myers Squibb only a month away from biopharma's biggest loss of exclusivity this year, industry watchers are eager for any clues about how the company's new and future medicines will perform on the market. The drugmaker has already launched two new CAR-T products, Breyanzi and Abecma, and now it's busy scaling up on the manufacturing front in a bid to meet early demand.